ARTICLE | Clinical News
RX-3117: Phase I started
March 19, 2012 7:00 AM UTC
Rexahn began a European Phase I trial to evaluate oral RX-3117 in cancer patients. Teva has exclusive, worldwide rights to develop and commercialize RX-3117 from Rexahn under a September 2009 deal (se...